Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 2/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 2/20 | 1.00 |
| ▸ | NEK2 | P51955 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | PIR | O00625 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Plx-4720 SCHEMBL29392465 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Plx-4720 SCHEMBL133733 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298760 | 0.95 | BRAF (0.90) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298198 | 0.94 | BRAF (0.88) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7868924 | 0.93 | BRAF (0.88) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298282 | 0.92 | BRAF (0.84) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299672 | 0.91 | BRAF (0.83) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298349 | 0.91 | BRAF (0.83) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL29355460 | 0.90 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL12891936 | 0.90 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522872-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20250034652-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-01-30 | — | — | US | claimed |
| US-12195771-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-01-14 | — | — | US | claimed |
| US-12146196-B2 | C-RAF mutants that confer resistance to RAF inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-11-19 | — | — | US | claimed |
| US-20240093310-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-21 | — | — | US | claimed |
| US-11788151-B2 | C-RAF mutants that confer resistance to RAF inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | claimed |
| US-11723891-B2 | Drug combinations for use in the treatment of RAS-mutant cancer | UMC UTRECHT HOLDING B.V. (NL) | 2023-08-15 | — | — | US | claimed |
| US-11590133-B2 | Methods and compositions for treatment of BRAF mutant cancers | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-02-28 | — | — | US | claimed |
| CN-114761006-A | Methods of treating cancer resistant to kinase inhibitors | INSERM(法国国家健康医学研究院) | 2022-07-15 | — | — | CN | claimed |
| US-20220195408-A1 | COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-06-23 | — | — | US | claimed |
| CN-114364798-A | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer | 欧恩科斯欧公司 | 2022-04-15 | — | — | CN | claimed |
| US-11286469-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-03-29 | — | — | US | claimed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20260124285-A1 | PERSONALIZED CANCER VACCINES | MODERNATX, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12582609-B2 | Cancer vaccines | MODERNATX, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4648793-A1 | PERSONALIZED CANCER VACCINES | ModernaTX, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20220125899-A1 | RNA CANCER VACCINES | MODERNATX, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| CN-114364798-A | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer | 欧恩科斯欧公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11286469-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582609-B2 | Cancer vaccines | RNMT, MICA, NSUN2 | BRAF 1940/4885RIPK2 3996/4885RAF1 1606/4885 |
| US-20220125899-A1 | RNA CANCER VACCINES | NSUN3, RNGTT, TP53 | BRAF 1038/4885RIPK2 4515/4885RAF1 1594/4885 |
| US-20260124285-A1 | PERSONALIZED CANCER VACCINES | PDCD1, CD274, PDCD1LG2 | BRAF 210/4885RIPK2 4267/4885RAF1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.